ADC Therapeutics came into this print as a deeply out of favor biotech, with the stock down about 69% over three months and trading just above US$1. The immediate reaction was another 3.8% slip after earnings, yet the headline this quarter is a sharply narrower loss rather than a fresh blowup.

Net loss fell to US$16.6m on US$19.2m of revenue, while cash of US$219.1m and management’s claim of runway into 2028 kept the balance sheet front and center. For a stock already priced for stress, this quarter was more about survival than surprise.

Love the narrower loss and extended cash runway at ADC Therapeutics but worried that the stock still feels like a high risk bet? Check out 83 resilient stocks with low risk scores to see how companies with stronger risk profiles compare.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$19.25m vs. US$18.84m (modest increase year over year)
• Net Loss (Q2 2026 vs Q2 2025): US$16.57m loss vs. US$56.65m loss (loss narrowed year over year)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.11 loss per share vs. US$0.50 loss per share (loss per share improved year over year)
• Cash Balance (Q2 2026 vs Q1 2026): US$219.1m vs. US$231.0m (cash position declined quarter over quarter)

Prefer clear visuals instead of another dense block of numbers and biotech jargon? See ADC Therapeutics' full financial picture, with a focus on its balance sheet strength, in the interactive company report for ADC Therapeutics.

ADC Therapeutics: Bulls Point To Resets And Runway

Optimistic investors argue ADC Therapeutics can outgrow LOTIS‑5 concerns through steady Zynlonta demand, cleaner trial execution and tight cost control. The quarter gives that view partial support. Zynlonta revenue of US$18.6m is broadly consistent with last year, which fits management’s claim that the LOTIS‑5 safety story has not yet hit prescribing in the current label. Operating expenses on a non GAAP basis fell 22% year over year and cash declined only modestly to US$219.1m, while management still talks about runway into 2028. LOTIS‑7 has hit a key milestone with 100 patients enrolled at the selected dose and data already submitted for ASH and publication, with a breakthrough designation filing planned this year. That execution, plus a further US$10m in expected annualized savings, supports the idea of a leaner company with enough time to see whether the Zynlonta combinations can pay off.

LOTIS‑5 Overhang Keeps ADC Therapeutics Bear Case Alive

The bearish story centers on Zynlonta being a single high risk asset with growing regulatory friction and limited growth proof points. Recent numbers still lean that way. Zynlonta revenue is essentially flat year over year, which does not yet answer concerns about commercial scalability. The FDA has raised “substantial concerns” about LOTIS‑5 benefit risk, and the company is now rethinking the regulatory route rather than moving cleanly toward full approval. That is a clear milestone missed for those expecting LOTIS‑5 to secure a broader second line label. Management insists LOTIS‑5 safety does not read through to LOTIS‑7 or monotherapy, but that remains a forward looking argument until more data and regulatory feedback land. The stock’s roughly 69% decline over 90 days and another 3.8% drop after earnings show that investors still treat the restructuring and cost cuts as signs of strain rather than a position of strength.

After a quarter in which ADC Therapeutics is managing a single key asset, regulatory questions and a sharply weaker share price, it is reasonable to ask whether these are isolated issues or part of a deeper pattern. Review our independent risk analysis for ADC Therapeutics which shows 2 important warning signs

Stay Ahead With Simply Wall St

If the mix of a narrower loss, LOTIS trial questions and a sharply weaker share price has put ADC Therapeutics on your radar, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a more attractive entry point. Once you decide to take a position, keep your decisions clear with the Portfolio Command Center which filters out noise and keeps you focused on key developments. For a broader view on ADC Therapeutics and similar stocks, tap into the Community to see how other investors are thinking through the same risks and potential catalysts. By spotting hidden pressures and early positives before they are widely discussed, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond ADC Therapeutics

Fresh stock ideas can move fast, and the strongest setups often fade once the crowd catches on. Scan these curated shortlists while the data is still sharp and act now.

• Spot companies quietly building momentum with resilient balance sheets by reviewing the curated list of solid balance sheet and fundamentals stocks (50 results) before they get fully priced in by the wider market.
• Zero in on income opportunities that aim to keep paying even when sentiment cools by checking the hand picked 10 dividend fortresses while yields still look appealing.
• Target growth stories outside the current headlines with the refined 18 high quality undiscovered gems to give yourself a chance to catch potential breakouts early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.